Articles

platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury...

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent

The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary...

Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results

AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose aspirin, at the American College of...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI

Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results...

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart...

The Medicines Company, cangrelor, FDA advisory committee, approval

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9 - 2 with one abstention to recommend approval of...

ivabradine (Corlanor)

The U.S. Food and Drug Administration (FDA) approved Amgen’s ivabradine (Corlanor) to reduce hospitalization from worsening heart failure.

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack...

A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing...